Cluster of neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016

Clinical Infectious Diseases

Volumn 65, Issue 6, 2017, Pages 918-923

  Katz, Alan R ^a,b   Komeya, Alan Y ^b   Kirkcaldy, Robert D ^c   Whelen, A Christian ^a,d   Soge, Olusegun O ^e   Papp, John R ^c   Kersh, Ellen N ^c   Wasserman, Glenn M ^a,b   O'Connor, Norman P ^d   O'Brien, Pamela S ^d   Sato, Douglas T ^d   Maningas, Eloisa V ^d   Kunimoto, Gail Y ^d   Tomas, Juval E ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b Hawaii Department of Health   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d State Laboratories Division   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antimicrobial drug resistance; Gonorrhea

Indexed keywords

AZITHROMYCIN; BETA LACTAMASE; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; PENICILLIN DERIVATIVE; TETRACYCLINE; ANTIINFECTIVE AGENT;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; EPSILOMETER TEST; FEMALE; GENETIC ANALYSIS; HAWAII; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PRIORITY JOURNAL; ADULT; COMBINATION DRUG THERAPY; CONTACT EXAMINATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GONORRHEA; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; TRANSMISSION; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BETA-LACTAMASES; CEFTRIAXONE; CIPROFLOXACIN; CONTACT TRACING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; GONORRHEA; HAWAII; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEISSERIA GONORRHOEAE; PENICILLINS; TETRACYCLINE; YOUNG ADULT;

EID: 85021989537     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix485     Document Type: Article

References (33)

1. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Available at: http://apps.who.int/iris/bitstream/10665/44863/1/9789241503501-eng.pdf. Accessed 15 March 2017.
2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-Threats-2013-508.pdf. Accessed 15 March 2017.
3. Centers for Disease Control and Prevention. CDC Grand Rounds: The growing threat of multidrug-resistant gonorrhea. MMWR Morb Mortal Wkly Rep 2013; 62: 103-6.
4. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:49-55.
5. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61: 590-4.
6. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:60-8.
7. Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011; 17:148-9.
8. Centers for Disease Control and Prevention. Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae-United States, 1988-1991. MMWR Surveill Summ 1993; 42:29-39.
9. Kidd S, Lee MV, Maningas E, et al. Gonococcal susceptibility to cephalosporins- Hawaii, 2003 to 2011. Sex Transm Dis 2013; 40:756-9.
10. Sarafian SK, Rice RJ, Ohye RG, Higa H, Knapp JS. Diversity of isolates of penicillinase- producing Neisseria gonorrhoeae (PPNG) in Honolulu, Hawaii: 1982-1991. Sex Transm Dis 1994; 21:332-7.
11. Knapp JS, Ohye R, Neal SW, Parekh MC, Higa H, Rice RJ. Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii. Antimicrob Agents Chemother 1994; 38:2200-3.
12. Wang SA, Lee MV, O'Connor N, et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001. Clin Infect Dis 2003; 37:849-52.
13. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 2012; 54:841-3.
14. Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance -The Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ 2016; 65:1-19.
15. Martin IM, Ison CA. Detection of mixed infection of Neisseria gonorrhoeae. Sex Transm Infect 2003; 79:56-8.
16. World Health Organization. Manual for the laboratory identification and antimicrobial susceptibility testing of bacterial pathogens of public health concern in the developing world, 2003: 63-102. Available at: http://www.who.int/csr/resources/publications/drugresist/WHO-CDS-CSR-RMD-2003-6/en/. Accessed 15 March 2017.
17. Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project (GISP) protocol, May 2016: 1-36. Available at: https://www.cdc.gov/std/gisp/gisp-protocol-may-2016.pdf. Accessed 15 March 2017.
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement (M100-S25). Wayne, PA: Clinical and Laboratory Standards Institute, 2015.
19. Etest [package insert]. Marcy-l'Etoile, France: bioMerieux; 2012. Available at: http://www.ilexmedical.com/files/E-Test-Package-Insert/AST-WW.pdf Accessed 15 March 2017.
20. Papp JR, Abrams AJ. Nash E, et al. Azithromycin resistance and decreased ceftriaxone susceptibility in Neisseria gonorrhoeae, Hawaii, USA. Emerg Infect Dis 2017; 23:830-2.
21. Liu H, Taylor TH Jr, Pettus K, Trees D. Assessment of Etest as an alternative to agar dilution for antimicrobial susceptibility testing of Neisseria gonorrhoeae. J Clin Microbiol 2014; 52:1435-40.
22. Shende T, Sood S, Singh R, Kapil A, Kar HK, Sharma VK. Comparison of Etest and agar dilution for testing activity of ceftriaxone against Neisseria gonorrhoeae. J Med Microbiol 2016; 65:701-2.
23. Biedenbach DJ, Jones RN. Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: investigation using 510(k) review criteria, recommended by the Food and Drug Administration. J Clin Microbiol 1996; 34:3214-7.
24. Gose S, Kong CJ, Lee Y, et al. Comparison of Neisseria gonorrhoeae MICs obtained by Etest and agar dilution for ceftriaxone, cefpodoxime, cefixime and azithromycin. J Microbiol Methods 2013; 95:379-80.
25. Kirkcaldy RD, Soge O, Papp JR, et al. Analysis of Neisseria gonorrhoeae azithromycin susceptibility in the United States by the Gonococcal Isolate Surveillance Project, 2005 to 2013. Antimicrob Agents Chemother 2015; 59: 998-1003.
26. Chisholm SA, Wilson J, Alexander S, et al. An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England. Sex Transm Infect 2016; 92:365-7.
27. Shimuta K, Unemo M, Nakayama S, et al. Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with highlevel ceftriaxone resistance. Antimicrob Agents Chemother 2013; 57:5225-32.
28. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: Detailed characterization of the first strain with highlevel resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538-45.
29. Tanaka M, Furuya R, Irie S, Kanayama A, Kobayashi I. High prevalence of azithromycin- resistant Neisseria gonorrhoeae isolates with a multidrug resistance phenotype in Fukuoka, Japan. Sex Transm Dis 2015; 42:337-41.
30. Nakayama S, Shimuta K, Furubayashi K, Kawahata T, Unemo M, Ohnishi M. New ceftriaxone-And multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan. Antimicrob Agents Chemother 2016; 60:4339-41.
31. Fifer H, Natarajan U, Jones L, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med 2016; 374:2504-6.
32. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014; 59:1083-91.
33. Centers for Disease Control and Prevention. Recommendations for the laboratory- based detection of Chlamydia trachomatis and Neisseria gonorrhoeae-2014. MMWR Recomm Rep 2014; 63:1-19.